Paper · 39031286

The roles of FGFR3 and c-MYC in urothelial bladder cancer.

Bogale DE. Discov Oncol, 2024. Cited by 20 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. The roles of FGFR3 and c-MYC in urothelial bladder cancer. Papers, record 39031286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39031286

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: The roles of FGFR3 and c-MYC in urothelial bladder cancer.; PubMed
Journal: Discov Oncol; PubMed
Year: 2024; PubMed
Publication types: Journal Article, Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/39031286/; PubMed
DOI: https://doi.org/10.1007/s12672-024-01173-z; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11264706/; PubMed
The journal: https://conductscience.org/library/journal-index/101775142; PubMed
Citations, by iCite: 20; iCite
Relative citation ratio, by iCite: 2.89, provisional; iCite
Revised in PubMed: 2024-07-25; PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Bogale DE	Dereje E

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References175

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	24,360,661	FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.	Urol Oncol	2014	https://conductscience.org/library/papers/24360661	PubMed
2	10,096,250	Over-expression and amplification of the c-myc gene in human urothelial carcinoma.	Int J Cancer	1999	https://conductscience.org/library/papers/10096250	PubMed
3	16,597,617	Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.	J Biol Chem	2006	https://conductscience.org/library/papers/16597617	PubMed
4	27,381,494	A place for precision medicine in bladder cancer: targeting the FGFRs.	Future Oncol	2016	https://conductscience.org/library/papers/27381494	PubMed
5	24,937,673	Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer.	Br J Cancer	2014	https://conductscience.org/library/papers/24937673	PubMed
6	33,317,057	Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.	Int J Mol Sci	2020	https://conductscience.org/library/papers/33317057	PubMed
7	24,302,556	Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.	Cancer Discov	2014	https://conductscience.org/library/papers/24302556	PubMed
8	34,508,258	The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.	Nat Rev Clin Oncol	2022	https://conductscience.org/library/papers/34508258	PubMed
9	26,869,289	Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.	Mol Cancer Res	2016	https://conductscience.org/library/papers/26869289	PubMed
10	32,260,326	Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc.	Cells	2020	https://conductscience.org/library/papers/32260326	PubMed

1 to 10 of 175

See all 175 references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMID	Title	Journal	Year	In Papers	Source
42,966,755	Conformational heterogeneity: a fundamental mechanism of adaptive phenotypic plasticity and therapeutic resistance.	Br J Cancer	2026	https://conductscience.org/library/papers/42966755	PubMed
42,941,789	pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42941789	PubMed
42,633,326	Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.	MedComm (2020)	2026	https://conductscience.org/library/papers/42633326	PubMed
42,470,241	Shared Genetics of Kidney Function Traits and Bladder Cancer: A Genome-Wide Cross-Trait Analysis.	Cancer Med	2026	https://conductscience.org/library/papers/42470241	PubMed
42,429,045	FGFR1 signaling in rheumatoid arthritis: Mechanisms of bone destruction and therapeutic targeting (Review).	Int J Mol Med	2026	https://conductscience.org/library/papers/42429045	PubMed
42,366,674	Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.	Oncologist	2026	https://conductscience.org/library/papers/42366674	PubMed
42,301,608	Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer.	Clin Transl Oncol	2026	https://conductscience.org/library/papers/42301608	PubMed
42,283,962	CHD6 promotes triple-negative breast cancer progression and is associated with PI3K/AKT and MAPK pathways.	Int J Clin Oncol	2026	https://conductscience.org/library/papers/42283962	PubMed
42,177,363	FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.	Commun Biol	2026	https://conductscience.org/library/papers/42177363	PubMed
41,681,916	FGFR Testing in Metastatic Urothelial Carcinoma-Who, When, and How to Test.	Cancers (Basel)	2026	https://conductscience.org/library/papers/41681916	PubMed

1 to 10 of 17

See all 17 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
FGFR3	2,261	PubTator's text mining	https://conductscience.org/library/genes/2261	NCBI Gene
MYC	4,609	PubTator's text mining	https://conductscience.org/library/genes/4609	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39031286

GET https://conductscience.org/api/papers/v1/39031286/references?page=2

API reference For AI assistants